PERSPECTA

News from every angle

← Back to headlines

Summit Therapeutics Stock Surges 28% on Clinical Progress for Ivonescimab

Shares of Summit Therapeutics jumped significantly after the company reported positive developments regarding its experimental drug ivonescimab.

7 Sept, 05:53 — 7 Sept, 05:53
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual2d ago

Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress

Read full article →

Related Stories

Greek Artist Giorgos Mazonakis Dies After Hospital Struggle

49m ago

Scientists Warn Hot Drinks Triple Esophageal Cancer Risk

1h ago

Bangladesh Measles Outbreak Kills Over 1,000 Children

2h ago

Greek Woman Gives Birth from Embryo Frozen for 22 Years

2h ago